A study on the impact of CYP2C19 genotype and platelet reactivity assay on patients undergoing PCI
Copyright © 2015 Cardiological Society of India. Published by Elsevier B.V. All rights reserved..
BACKGROUND: A thorough understanding of the patient's genotype and their functional response to a medication is necessary for improving event free survival. Several outcome studies support this view particularly if the patient is to be started on clopidogrel due to the prevalence of clopidogrel resistance. Such guided therapy has reduced the incidence of Major Adverse Cardiac Events (MACE) after stent implantation.
METHODS: Between August 2013 and August 2014, 200 patients with coronary artery disease undergoing percutaneous coronary intervention (PCI) were prescribed any one of the anti-platelet medications such as clopidogrel, prasugrel or ticagrelor and offered testing to detect CYP2C19 gene mutations along with a platelet reactivity assay (PRA). Intended outcome was modification of anti-platelet therapy defined as either dose escalation of clopidogrel or replacement of clopidogrel with prasugrel or ticagrelor for the patients in clopidogrel arm, and replacement of ticagrelor or prasugrel with clopidogrel if those patients were non-carrier of mutant genes and also if they demonstrated bleeding tendencies in the ticagrelor and prasugrel arms.
CONCLUSION: Clopidogrel resistance was observed to be 16.5% in our study population. PRA was useful in monitoring the efficacy of thienopyridines. By having this test, one can be safely maintained on clopidogrel in non-carriers, or with increased dose of clopidogrel in intermediate metabolizers or with newer drugs such as ticagrelor or prasugrel in poor metabolizers. Patients on ticagrelor and prasugrel identified as non-carriers of gene mutations for clopidogrel metabolism could be offered clopidogrel resulting in economic benefits to the patients. Patients at high risk of bleeding were also identified by the PRA.
| Errataetall: |
CommentIn: Indian Heart J. 2015 Mar-Apr;67(2):93-4. - PMID 26071284 |
|---|---|
| Medienart: |
E-Artikel |
| Erscheinungsjahr: |
2015 |
|---|---|
| Erschienen: |
2015 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:67 |
|---|---|
| Enthalten in: |
Indian heart journal - 67(2015), 2 vom: 01. März, Seite 114-21 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Rath, P C [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 13.12.2016 Date Revised 02.12.2018 published: Print-Electronic CommentIn: Indian Heart J. 2015 Mar-Apr;67(2):93-4. - PMID 26071284 Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.ihj.2015.03.017 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM249927403 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM249927403 | ||
| 003 | DE-627 | ||
| 005 | 20231224154633.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231224s2015 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.ihj.2015.03.017 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n0833.xml |
| 035 | |a (DE-627)NLM249927403 | ||
| 035 | |a (NLM)26071289 | ||
| 035 | |a (PII)S0019-4832(15)00084-X | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Rath, P C |e verfasserin |4 aut | |
| 245 | 1 | 2 | |a A study on the impact of CYP2C19 genotype and platelet reactivity assay on patients undergoing PCI |
| 264 | 1 | |c 2015 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 13.12.2016 | ||
| 500 | |a Date Revised 02.12.2018 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a CommentIn: Indian Heart J. 2015 Mar-Apr;67(2):93-4. - PMID 26071284 | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2015 Cardiological Society of India. Published by Elsevier B.V. All rights reserved. | ||
| 520 | |a BACKGROUND: A thorough understanding of the patient's genotype and their functional response to a medication is necessary for improving event free survival. Several outcome studies support this view particularly if the patient is to be started on clopidogrel due to the prevalence of clopidogrel resistance. Such guided therapy has reduced the incidence of Major Adverse Cardiac Events (MACE) after stent implantation | ||
| 520 | |a METHODS: Between August 2013 and August 2014, 200 patients with coronary artery disease undergoing percutaneous coronary intervention (PCI) were prescribed any one of the anti-platelet medications such as clopidogrel, prasugrel or ticagrelor and offered testing to detect CYP2C19 gene mutations along with a platelet reactivity assay (PRA). Intended outcome was modification of anti-platelet therapy defined as either dose escalation of clopidogrel or replacement of clopidogrel with prasugrel or ticagrelor for the patients in clopidogrel arm, and replacement of ticagrelor or prasugrel with clopidogrel if those patients were non-carrier of mutant genes and also if they demonstrated bleeding tendencies in the ticagrelor and prasugrel arms | ||
| 520 | |a CONCLUSION: Clopidogrel resistance was observed to be 16.5% in our study population. PRA was useful in monitoring the efficacy of thienopyridines. By having this test, one can be safely maintained on clopidogrel in non-carriers, or with increased dose of clopidogrel in intermediate metabolizers or with newer drugs such as ticagrelor or prasugrel in poor metabolizers. Patients on ticagrelor and prasugrel identified as non-carriers of gene mutations for clopidogrel metabolism could be offered clopidogrel resulting in economic benefits to the patients. Patients at high risk of bleeding were also identified by the PRA | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Multicenter Study | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a CYP2C19 genotype | |
| 650 | 4 | |a PCI | |
| 650 | 4 | |a Platelet reactivity assay | |
| 650 | 7 | |a Platelet Aggregation Inhibitors |2 NLM | |
| 650 | 7 | |a Purinergic P2Y Receptor Antagonists |2 NLM | |
| 650 | 7 | |a DNA |2 NLM | |
| 650 | 7 | |a 9007-49-2 |2 NLM | |
| 650 | 7 | |a Clopidogrel |2 NLM | |
| 650 | 7 | |a A74586SNO7 |2 NLM | |
| 650 | 7 | |a Cytochrome P-450 CYP2C19 |2 NLM | |
| 650 | 7 | |a EC 1.14.14.1 |2 NLM | |
| 650 | 7 | |a Prasugrel Hydrochloride |2 NLM | |
| 650 | 7 | |a G89JQ59I13 |2 NLM | |
| 650 | 7 | |a Ticagrelor |2 NLM | |
| 650 | 7 | |a GLH0314RVC |2 NLM | |
| 650 | 7 | |a Adenosine |2 NLM | |
| 650 | 7 | |a K72T3FS567 |2 NLM | |
| 650 | 7 | |a Ticlopidine |2 NLM | |
| 650 | 7 | |a OM90ZUW7M1 |2 NLM | |
| 700 | 1 | |a Chidambaram, Sundar |e verfasserin |4 aut | |
| 700 | 1 | |a Rath, Pallavi |e verfasserin |4 aut | |
| 700 | 1 | |a Dikshit, Byomakesh |e verfasserin |4 aut | |
| 700 | 1 | |a Naik, Sudhir |e verfasserin |4 aut | |
| 700 | 1 | |a Sahoo, Prashant K |e verfasserin |4 aut | |
| 700 | 1 | |a Das, Brajraj |e verfasserin |4 aut | |
| 700 | 1 | |a Mahalingam, Mohanshankar |e verfasserin |4 aut | |
| 700 | 1 | |a Khandrika, Lakshmipathi |e verfasserin |4 aut | |
| 700 | 1 | |a Jain, Jugnu |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Indian heart journal |d 1961 |g 67(2015), 2 vom: 01. März, Seite 114-21 |w (DE-627)NLM000004162 |x 2213-3763 |7 nnns |
| 773 | 1 | 8 | |g volume:67 |g year:2015 |g number:2 |g day:01 |g month:03 |g pages:114-21 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.ihj.2015.03.017 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 67 |j 2015 |e 2 |b 01 |c 03 |h 114-21 | ||